SMALL CELL LUNG CANCER . CREAN ETOPOSIDE INHALADO COMO TRATAMIENTO DE INDUCCIÓN EN PRIMERA LINEA COMBINADO CON PLATINO , ATEZOLIZUMAB O DURVALUMAB : *.- REDUCE MÁS LOS EFECTOS ADVERSOS ... *.- INDUCIR APOPTOSIS ... *. SER MUCHÍSIMO MÁS COMODO PARA L@S PACIENTES ...

P.J. : OJALÁ Y POR EL BIEN DE L@s PACIENTES ... ETOPOSIDE INHALADO PUEDA MEJORAR LA OVERALL SURVIVAL , LA PFS Y ENCIMA PUEDA DISMINUIR LOS EFECTOS SECUNDARIOS ... 

MÁS  AÚN TRATÁNDOSE DEL ÚNICO TRATAMIENTO ESTÁNDAR DE PRIMERA LÍNEA DE INDUCCIÓN SMALL CELL LUNG CANCER EXTENSIVE-STAGE Y QUE COMO TOD@S YA SABEMOS ES :

ETOPOSIDE COMBINADO CON PLATINO MÁS ATEZOLIZUMAB O DURVALUMAB .

Pharmaceutics, Drug Delivery and Pharmaceutical Technology | Research Article .

Enhancing The Bioavailability And Targeting Of Etoposide As A Potential Small Cell Lung Cancer Treatment .

 

Highlights

•

The Small HALF-LIFE And Poor Bioavailability Of ORAL ETOPÓSIDO Causes Its Low Efficacy .

•

The INHALED ELP Enhanced The Sustainability And Bioavailability Of ETOPÓSIDO .

•

The INHALED ELP Enhanced ETP’s Accumulation In The LUNG .

Abstract

Etoposide (ETP) is a Topoisomerase II Enzyme Inhibitor With Excellent Activity Against SMALL CELL LUNG CANCER ( SCLC ) .

 However, The Low Aqueous Solubility, Short HALF-LIFE, And Nonspecific Toxicities Of ETOPÓSIDO Limit Its Bioavailability And Efficacy .

 Hence, a NEBULIZED Formulation Of ETOPÓSIDO-LOADED Proniosomes ( ELP ) Was developed to enhance The Sustainability, Bioavailability, Targeting, And Efficacy Of ETP As a Potential Therapy For SMALL CELL LUNG CANCER .

Various ELP Formulations Were Fabricated Using The Box-Behnken Design And Then Assessed In Vitro To Determine The Optimized ELP Formulation .

 The Optimized ELP Formulation Was Subsequently Assessed For Its Cytotoxicity, Pharmacokinetics, Biodistribution, And Toxicity Investigations .

 ELP Formulation Had a Surfactant With HLB of 6.84, a Ratio of Cholesterol/Surfactant Of 1.52, And a Ratio Of Surfactant/Lactose Of 4.01 Was Chosen As An Optimized Formulation .

In Comparison To Free ETOPÓSIDO , The Optimized ELP Formulation Increased The Sustainability Of ETP By 2.55-Fold And Showed To Induce Substantial APOPTOSIS in The A-549 LUNG CANCER CELL LINE .

 The Optimized ELP Formulation Markedly Increased The Bioavailability Of ETP By 6.71-Fold And Booster its Targeting Capability .

 The NEBULIZED Administration Of The Optimized ELP Formulation Did Not Induce Toxicity In Healthy Animals .

NEBULIZED Administration Of The Optimized ELP Formulation Could Be a Safe And Potential Therapy For SMALL CELL LUNG CANCER .